Covalon To Host Symposium On Chronic Wound Management At Ewma 2016 In Bremen, Germany

MISSISSAUGA, Ontario – May 11, 2016 – /Business Wire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced its participation at the European Wound Management Association (“EWMA”) annual conference, including the sponsorship of a satellite symposium entitled “Management of Proteases in the Chronic Wound” presented by Dr. Terry Treadwell, MD, FACS, Medical Director, Institute for Advanced Wound Care.

“We hope all delegates with an interest in healing recalcitrant wounds will attend Dr. Treadwell’s talk.” said John R. Hands, Executive Vice President of Covalon. Dr. Treadwell’s presentation will take place on Thursday May 12 at 3:45pm in the Franzius room.

“We also invite everyone to stop by Covalon’s booth 5K13 to learn about our advanced wound care portfolio, which includes our CovaWound line of products and ColActive Plus, our patented biomatrix dressing proven to reduce elevated protease activity in a chronic wound, a known cause of wound chronicity” Hands continued.

In addition to the symposium, there will be three scientific posters presented on Covalon’s products at this year’s EWMA:

- An *in vitro* analysis of the antimicrobial activity of a silver containing collagen dressing over seven days - Dr. Casandra Gardner.
- Assessment of a novel biomatrix wound contact layer using simulated NPWT – Dr. Casandra Gardner.
- The antimicrobial protective properties of a novel pre-operative skin preparation product with chlorhexidine and silver – Dr. Casandra Gardner.

“The timing of EWMA presents a great opportunity for us to build on our successful presence at the SAWC Spring congress last month in Atlanta. This is our second year exhibiting at EWMA and we see an immediate need in the European market for our CovaWound line of advanced wound care products.” said Hands.

Covalon will also be showcasing its dual antimicrobial clear silicone adhesive technologies including SurgiClear™ Antimicrobial Post Op Dressing. SurgiClear’s combination of chlorhexidine and silver is proven to have a synergistic effect against some of the most common surgical site infection bacteria[i] and SurgiClear’s soft silicone adhesive will not cause adhesive related skin injury or pain during dressing changes[ii].

Visit Covalon at booth 5K13 at the EWMA Conference May 11-13 at Messe Bremen, Germany.

To learn more about Covalon, please contact:

Brian Pedlar, CEO, Covalon Technologies Ltd.

Email: bpedlar@covalon.com

Phone: 905.568.8400 x 233

Toll free: 1.877.711.6055

Web site: www.covalon.com

Twitter: @covalon

About Covalon

Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at www.covalon.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of

words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.

---

https://ir.covalon.com/press-releases?item=205